Related Experiment Video
Updated: Jul 9, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Elranatamab: A novel B-cell maturation T-cell engager.
Shahrier Hossain1, Giada Bianchi1,2
1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Human Vaccines & Immunotherapeutics
|July 8, 2026
Summary
Elranatamab, a bispecific antibody, targets B-cell maturation antigen (BCMA) on multiple myeloma cells. It activates T cells to kill cancer cells, showing efficacy and a favorable safety profile.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- B-cell maturation antigen (BCMA) is a key survival target on malignant plasma cells in multiple myeloma.
- Novel immunotherapies targeting BCMA offer promising treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of elranatamab, a bispecific antibody targeting BCMA and CD3.
- To assess elranatamab's role in relapsed/refractory multiple myeloma.
Main Methods:
- Elranatamab administration targets BCMA on plasma cells and CD3 on T cells, inducing targeted cell killing.
- Monitoring for immune-related adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Main Results:
- Elranatamab demonstrates robust efficacy in patients with relapsed/refractory multiple myeloma.
- The agent exhibits a favorable safety profile compared to similar therapies.
Conclusions:
- Elranatamab is an effective treatment for relapsed/refractory multiple myeloma.
- Ongoing trials are exploring elranatamab in combination therapies and earlier treatment lines.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.